Pirarubicin

Pirarubicin
Clinical data
Other names	(9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
AHFS/Drugs.com	International Drug Names
ATC code	L01DB08 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranoside;
CAS Number	72496-41-4 ;
PubChem CID	3033521;
ChemSpider	2298189 ;
UNII	D58G680W0G;
KEGG	D01885 ;
ChEMBL	ChEMBL1398373 ;
CompTox Dashboard (EPA)	DTXSID2046755 ;
Chemical and physical data
Formula	C32H37NO12
Molar mass	627.643 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	188 to 192 °C (370 to 378 °F) (decomposes)
	SMILES C[C@H]1[C@H]([C@H](C[C@@H](O1)OC2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O[C@@H]6CCCCO6;
	InChI InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19?,21+,22-,31+,32-/m0/s1 ; Key:KMSKQZKKOZQFFG-YHKVCKOMSA-N ;
	(what is this?) (verify)

Pirarubicin (INN) is an anthracycline drug. An analogue of the anthracycline antineoplastic antibiotic doxorubicin. Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines.^[1]

References

↑ Miller AA, Salewski E (1994). "Prospects for pirarubicin". Medical and Pediatric Oncology. 22 (4): 261–8. doi:10.1002/mpo.2950220410. PMID 8107658.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid8107658-1] Miller AA, Salewski E (1994). "Prospects for pirarubicin". Medical and Pediatric Oncology. 22 (4): 261–8. doi:10.1002/mpo.2950220410. PMID 8107658.

[1]